Overview
Hemab Therapeutics has raised $157M in a Series C round on Oct 27, 2025, with participation from Sofinnova Partners. The company pioneering therapies for bleeding disorders that medicine left behind. The round will be used to accelerate product development, expand the team, and scale go-to-market operations.
Operating in the biotechnology research sector, Hemab Therapeutics is positioned to capitalize on growing demand for innovative solutions in this space. With fresh capital, the company is expected to invest heavily in R&D and talent acquisition, signaling a period of aggressive growth ahead.
Market Outlook
This funding positions Hemab Therapeutics as one to watch in the biotechnology research landscape. As the company scales, it will likely become an increasingly attractive partner — and customer — for B2B vendors looking to sell into well-funded, growth-stage companies. The post-raise window of 60-90 days is typically when startups are most receptive to new tools, services, and partnerships.
Why contact Hemab Therapeutics now
Hemab Therapeutics just closed $157M in Series C funding — which means they're actively scaling their team, upgrading their tech stack, and looking for vendors who can help them move fast. Companies at this stage typically make purchasing decisions within 60-90 days of closing a round. If you sell to biotechnology research companies, this is your window to reach out before competitors do.
Founders & Contacts
Investors
Company Facts
| Company | Hemab Therapeutics |
| Amount Raised | $157M |
| Funding Round | Series C |
| Date Raised | Oct 27, 2025 |
| Founded | 2020 |
| Industry | Biotechnology Research |
| Founders |
Get Verified Founder Emails
Access verified email addresses and contact details for Hemab Therapeutics's founders and thousands of other funded startups.
Start Free Trial